Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is at the forefront of developing personalized cancer immunotherapies and next-generation vaccines for infectious diseases. Headquartered in Emeryville, California, with additional key functions in Cambridge, Massachusetts, Gritstone is a clinical-stage biotechnology company leveraging innovative vectors and payloads to train the immune system to combat critical disease targets. Founded in 2015 with a strong financial backing of $102 million in Series A financing, Gritstone brings together a distinguished team of scientific founders, an experienced management team, and a successful board of directors.
Gritstone's pipeline includes multiple product candidates targeting solid tumors and viral diseases. Their key programs include GRANITE, a personalized neoantigen vaccine program, and SLATE, an 'off-the-shelf' neoantigen vaccine program. Additionally, they are developing CORAL, a next-generation SARS-CoV-2 vaccine designed to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA). Gritstone's collaboration with the National Cancer Institute (NCI) and other industry leaders underscores the pioneering vision and scientific rigor that guides their innovative approaches.
Recent clinical updates have highlighted promising preliminary Phase 2 data for GRANITE in metastatic colorectal cancer (MSS-CRC), showing a progression-free survival benefit. SLATE-KRAS, a variant of their 'off-the-shelf' neoantigen vaccine, has also demonstrated superior immunogenicity in Phase 2 studies. Additionally, their CORAL program continues to show robust and durable immune responses in diverse populations, including those living with HIV.
Gritstone's financial condition remains strong, bolstered by recent public offerings and continued support from prominent foundations and government agencies. Their latest corporate developments and financial results reflect a clear trajectory towards advancing their clinical programs and achieving regulatory milestones.
Gritstone bio, Inc. (GRTS) announced significant advances in its clinical programs during its fourth quarter and full-year 2021 report. The company initiated four clinical trials for its CORAL COVID-19 vaccine program and advanced its oncology programs, GRANITE and SLATE, into Phase 2/3 trials for colorectal cancer. As of December 31, 2021, Gritstone reported cash and equivalents of $223.5 million. Collaboration revenue surged to $46.7 million from $3.5 million the previous year, largely due to a partnership with Gilead. The firm anticipates robust data updates throughout 2022.
Gritstone bio, Inc. (Nasdaq: GRTS) announced three accepted abstracts for the upcoming AACR Annual Meeting 2022, focusing on their KRAS-specific vaccine candidate, SLATE-KRAS, now in Phase 2 testing for solid tumors. An oral presentation by Dr. Christine D Palmer will discuss improved immunogenicity based on translational immunology data. The meeting will occur from April 8-13, 2022, in New Orleans, Louisiana, showcasing advancements in their GRANITE and SLATE programs, which utilize individualized and shared neoantigens to target cancer cells.
Gritstone bio, a clinical-stage biotechnology company (Nasdaq: GRTS), announced that CEO Andrew Allen will participate in the "Infectious Disease" panel at the Cowen 42nd Annual Health Care Conference virtually from March 7-9, 2022. The panel is scheduled for March 9 from 10:30 to 11:30 a.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. Gritstone bio focuses on innovative immunotherapies for cancer and infectious diseases, leveraging machine learning technology to develop targeted treatments.
On February 8, 2022, Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options to five new employees, totaling 35,400 shares at an exercise price of $5.46, equal to the stock's closing price on January 31, 2022. The options vest over four years, with 25% vesting after one year and monthly thereafter, contingent on continued employment. This initiative is part of their 2021 Employment Inducement Incentive Award Plan, aimed at attracting talent in the competitive biotech landscape.
Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology firm, announced that its Co-founder and CEO, Andrew Allen, will join a panel on precision oncology at the 2022 BIO CEO & Investor Conference in New York City. The discussion titled "Treating Cancer Through Precision Oncology" will be held on February 14, 2022, from 11 a.m. to 11:45 a.m. EST and will be accessible to registrants. Gritstone is focused on developing innovative immunotherapies for cancer and infectious diseases, leveraging its proprietary Gritstone EDGE platform.
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options for 63,400 shares to eleven employees, with an exercise price of $6.30 per share, reflecting the stock's closing price on January 13, 2022. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and supports new hires at Gritstone. The company focuses on developing immunotherapies for cancer and infectious diseases using its proprietary platform, Gritstone EDGE.
Gritstone bio has commenced the Phase 2/3 GRANITE-CRC-1L trial, targeting newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial is designed with registrational intent and has received Fast Track designation from the FDA. Updated data from prior trials indicate a positive correlation between circulating tumor DNA (ctDNA) reduction and overall survival. Initial data from this trial is expected by mid-2023, showcasing the potential of the GRANITE vaccine in frontline cancer therapy.
Gritstone bio (Nasdaq: GRTS) announced positive Phase 1 results for its CORAL-BOOST study, demonstrating robust neutralizing antibody responses and broad CD8+ T cell responses from a 10 µg dose of its samRNA vaccine in healthy adults aged 60 and above, previously vaccinated with AstraZeneca’s COVID-19 vaccine. The vaccine was well-tolerated with no severe adverse events. The study will expand to 120 subjects, aiming to accelerate advancement into pivotal trials. The results indicate potential for enhanced immunity against SARS-CoV-2 variants.
Gritstone bio (Nasdaq: GRTS) announced participation in key investor conferences in January 2022. Notable events include the JP Morgan 40th Annual Global Healthcare Conference on January 13 at 8:15 a.m. ET and the H.C. Wainwright BioConnect Conference starting January 10. Presentations will be led by Andrew Allen, CEO. The B. Riley Securities' Virtual Oncology Conference occurs on January 27 at 1:30 p.m. ET. All presentations will be available via live webcasts and archived for 30 days on the company’s website, reinforcing Gritstone’s commitment to advancing cancer and infectious disease therapies.
Gritstone bio (Nasdaq: GRTS) announced changes to its Board of Directors, effective January 1, 2022. Clare Fisher, current SVP at BeiGene, will join the Board, bringing over 20 years of biotech experience. She is expected to enhance business development efforts at Gritstone. Meanwhile, Judith J. Li will depart from the Board after contributing since 2017, particularly in the Series B financing. This shift aims to strengthen leadership as Gritstone advances its next-generation immunotherapies targeting cancer and infectious diseases.
FAQ
What is the current stock price of Gritstone bio (GRTS)?
What is the market cap of Gritstone bio (GRTS)?
What does Gritstone bio, Inc. specialize in?
Where is Gritstone bio, Inc. headquartered?
What are Gritstone's key product candidates?
What recent clinical updates has Gritstone reported?
Who are Gritstone bio's collaborators?
When was Gritstone bio founded, and how was it funded?
What makes Gritstone's vaccines unique?
How does Gritstone's financial condition look?
What is the significance of the CORAL program?
What is the future outlook for Gritstone bio?
